Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

NCT05963932
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986419 DR Capsule, BMS-986419 IR Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

NCT06181084
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Esomeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

NCT03247517
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 200mg SPN-812, 400mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Dothan, Alabama • Orange, California • Hialeah, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

NCT05738850
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Healthy Participants
Interventions
ABBV-932, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 18, 2026, 2:41 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Food Effect Study of Two Formulations of TAK-906

NCT04831502
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

NCT05051553
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fedratinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 18, 2026, 2:41 PM EDT
Completed No phase listed Observational

The Visceral Adiposity Measurement and Observation Study

NCT05383456
View directory record Official record
Conditions
HIV, HIV-Infections, HIV-1-infection, HIV I Infection, HIV Lipodystrophy, HIV Infection Primary, HIV-Associated Lipodystrophy, HIV Disease Progression, Lipohypertrophy, Liver Diseases, NAFLD, NASH, Liver Fibrosis, Hepatic Fibrosis, Waist Circumference, BMI, Ectopic Fat, Liver Fat, Hepatic Steatosis
Interventions
Diagnostic Test, HIV Anti-retroviral Background Therapy
Diagnostic Test · Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Miami Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional

DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery

NCT00596583
View directory record Official record
Conditions
Mature Cataracts
Interventions
DYME
Drug
Lead sponsor
Aqumen Biopharmaceuticals, N.A.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Fayetteville, Arkansas • Inglewood, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Oct 18, 2026, 2:41 PM EDT
Not listed Not applicable Interventional

Comparison of the Atmo Motility Gas Capsule System to the Reference Standard

NCT05718505
View directory record Official record
Conditions
Gastroparesis, Slow Transit Constipation, IBS
Interventions
Atmo Motility Gas Capsule System, SmartPill Monitoring System
Device
Lead sponsor
Atmo Biosciences Pty Ltd
Industry
Eligibility
22 Years to 80 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 4 Interventional

Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

NCT00665327
View directory record Official record
Conditions
Pneumonia
Interventions
Avelox (Moxifloxacin, BAY12-8039), Levofloxacin
Drug
Lead sponsor
Bayer
Industry
Eligibility
65 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
76
States / cities
Mobile, Alabama • Tucson, Arizona • Brea, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 18, 2026, 2:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population

NCT06837246
View directory record Official record
Conditions
Cognition, Concentration, Attention, Focus
Interventions
Cognitive Nutritional Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Pharmavite LLC
Industry
Eligibility
25 Years to 65 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 18, 2026, 2:41 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

NCT04987762
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Adhansia XR
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
4 Years to 12 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

NCT03381664
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients

NCT00608244
View directory record Official record
Conditions
Liver Failure
Interventions
LCP Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

RDEA3170 Tablet and Capsule Bioavailability Study

NCT02448368
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170, 10 mg, RDEA3170, 2.5 mg, RDEA3170, 5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of Morcher Artificial Iris Diaphragms

NCT00812708
View directory record Official record
Conditions
Aniridia, Iris; Deformity
Interventions
Morcher iris diaphragm implantation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Training on Central Auditory Function in Multiple Sclerosis

NCT01023074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Auditory training, MS: Control Activity
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®

NCT04708951
View directory record Official record
Conditions
Adenoma, Colorectal Cancer
Interventions
ENDOCUFF VISION® device, G-EYE® colonoscope
Device
Lead sponsor
Dr. Horst Schmidt Klinik GmbH
Industry
Eligibility
Not listed
Enrollment
970 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 4 Interventional Results available

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

NCT03502070
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, Tobi Podhaler
Drug · Device
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Miami, Florida • Orlando, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

NCT00301236
View directory record Official record
Conditions
ADHD, ADD
Interventions
Dexmethylphenidate HCl extended-release capsules
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
252 participants
Timeline
2006
U.S. locations
25
States / cities
Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of ACH-0145228

NCT04709081
View directory record Official record
Conditions
Healthy
Interventions
ACH-0145228, Midazolam, Digoxin, Itraconazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Electrical Stimulation of the Internal Capsule for Intractable Depression

NCT01069952
View directory record Official record
Conditions
Depression
Interventions
Deep Brain Stimulation System
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 18, 2026, 2:41 PM EDT
Completed No phase listed Observational

Evaluation of Gastrointestinal Motility With SmartPill

NCT01159002
View directory record Official record
Conditions
Gastrointestinal Motility
Interventions
SmartPill
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine

NCT07465731
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Centanafadine SR, Centanafadine QD XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 18, 2026, 2:41 PM EDT